Company environment · Patent and exclusivity · in-house counsel
In-house patent counsel Hatch-Waxman patent-term extension election
Commercial small-molecule antiviral; PTE election audit for executive portfolio review.
1What does this company do?
In-house pharmaceutical patent counsel managing Orange Book exclusivity and Patent Term Extension (PTE) elections for a marketed small-molecule antiviral.
2Where is the product on its way to patients?
Commercial small-molecule antiviral with an executed Patent Term Extension (PTE) election under 35 U.S.C. § 156.
- 1Discovery & Lead Selection
- 2IND-Enabling Nonclinical
- 3Clinical Development (IND / CTA)
- 4Registration & Dossier Review
- 5Approval & Launch Readiness
- 6Commercial Lifecycle & GMP
- The product is here
3What is happening right now?
Executive portfolio review requires a formal decision record proving the PTE election maximized enforceable exclusivity.
4Tasks
1 task in the 81-task Biopharma Bench V0.2 suite, graded against expert rubric criteria.
Sealed partner records & open showcases
This environment is reconstructed from a confidential drug or device program, so its records, tasks, and rubrics remain sealed.
To inspect complete workspaces, candidate deliverables, trajectories, and rubric criteria end to end, open the two public companion showcases:
Havenor Therapeutics (synthetic sterile-injectables CMC/MSAT) →
Broad Institute (public FDA CDER IND 167326 record) →